Amyl Therapeutics is a preclinical-stage biotechnology compagny pioneering a breakthrough approach to treating rare and severe peripheral protein misfolding diseases.
By developing novel therapies that recognize and target multiple misfloded proteins, they aim to make a transformative impact on the lives of patients affected by systemic amaloidosis.
98 Rue Del Rodge Cinse - 4102 Seraing, Belgium